zts stock symbol: Zoetis (ZTS) Guide

ZTS (Zoetis Inc.)

zts stock symbol appears in equity markets as the ticker for Zoetis Inc., a global animal health company traded on the New York Stock Exchange. This article explains the zts stock symbol and provides a comprehensive, beginner-friendly guide to Zoetis’s business, corporate history, financial profile, trading mechanics and investor resources. Readers will learn where the ticker trades, what the company does, key milestones that affected the stock, how to monitor price and fundamental metrics, and where to go for up-to-date data. The coverage focuses on the stock listing and related market information — not on unrelated or ambiguous uses of the same letters.

Company overview

Zoetis Inc. is a global animal health company focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and related services for companion animals and livestock. The company's portfolio includes parasiticides, anti-infectives, vaccines, diagnostics, genetic tests, precision-animal-health solutions and devices for use by veterinarians, livestock producers and pet owners.

Headquartered in Parsippany, New Jersey, Zoetis traces its corporate roots to established animal-health operations within large pharmaceutical firms before becoming a standalone public company. The company operates in major markets across North America, Europe, Latin America and the Asia-Pacific region. Zoetis serves a mix of companion-animal customers (dogs, cats, horses) and production animals (cattle, swine, poultry) with both pharmaceutical and diagnostic offerings.

As a public company, the zts stock symbol represents investor ownership in Zoetis and is widely followed by market participants interested in the veterinary and animal-health sector.

Stock symbol and listings

• Ticker: ZTS (commonly quoted in lowercase or uppercase; many quotes use the exchange prefix, for example XNYS:ZTS). The primary listing for the zts stock symbol is the New York Stock Exchange (NYSE).
• Primary exchange code: NYSE (sometimes shown as XNYS in market-data systems).
• Trading currency: U.S. dollars (USD) for the primary listing.
• Share classes: Zoetis issues a single class of common stock that trades under the zts stock symbol. There are no publicly traded dual-class shares for Zoetis; investors buy and sell the common shares represented by ticker ZTS.

Market data providers and brokerage platforms will commonly display quotes as "ZTS" or as "XNYS:ZTS" to indicate the listing exchange. When checking quotes, confirm the exchange prefix if you use a platform that lists multiple exchanges or global tickers.

ISIN and market identifiers

• ISIN: Zoetis common stock has an International Securities Identification Number (ISIN) used by global market-data providers. For precise ISIN and CUSIP values, consult official company filings or market-data services. These identifiers are typically shown on investor relations pages and in regulatory filings so custodians or settlement systems can correctly reference the ticker.

Note: As an investor or data consumer, you can verify the ISIN and CUSIP in the company’s SEC filings (such as the Form 10-K) or in data feeds from recognized market-data vendors.

Corporate history and major milestones

Zoetis’s history includes a transition from a business unit inside a large pharmaceutical firm to an independent, publicly traded leader in animal health. Key milestones that shaped the company and the zts stock symbol include:

• Early history and formation: Zoetis’s business traces back through predecessor animal-health operations of major pharmaceutical companies. Over decades these operations developed veterinary medicines and diagnostics.

• Separation and IPO (2013): Zoetis became an independent publicly traded company in 2013 following a separation from a larger pharmaceutical parent. The initial public offering and listing of the zts stock symbol marked a major corporate milestone and opened the company to public equity investors. As of February 1, 2013, Zoetis began trading under ZTS on the NYSE (company investor relations provides the official timeline).

• Product and geographic expansion: Since independence, Zoetis has expanded its product portfolio through internal R&D and targeted acquisitions, broadening its reach in companion-animal treatments, livestock vaccines and diagnostics, and precision-health solutions.

• Acquisitions: Over the years Zoetis has acquired businesses and assets to strengthen its diagnostics and pharmaceutical pipelines — transactions that management identifies in annual reports and investor presentations. Large acquisitions and portfolio transactions have sometimes been material events for the zts stock symbol, affecting revenue composition and investor expectations.

• Innovation and technology: Zoetis has invested in genetics, diagnostics and digital/precision animal-health capabilities, reflecting industry trends toward data-driven veterinary care and herd-level disease monitoring.

• Shareholder-return initiatives: Zoetis has pursued dividend programs and share-repurchase authorizations as part of its capital-allocation framework — actions documented in investor materials and press releases that can influence investor sentiment toward the zts stock symbol.

For precise dates and transaction details, consult Zoetis investor relations and the company’s SEC filings, which provide legal and timing specifics for material events.

Business segments and products

Zoetis organizes its offerings around major product categories and customer segments. The principal categories include:

• Pharmaceuticals: Branded and generic therapeutics for parasite control, anti-infectives, anti-inflammatories and other pharmacologic categories used in companion animals and production livestock.

• Vaccines: Preventive vaccines for a range of infectious diseases in both companion animals and production animals.

• Diagnostics: In-clinic diagnostic instruments and test kits used by veterinarians for disease detection and monitoring. Diagnostics can include point-of-care analyzers and lab services.

• Genetic tests and services: Molecular and genetic testing for inherited conditions, pathogen typing and other services that support veterinary decisions and breeding programs.

• Precision animal health and digital services: Software and sensor-based monitoring solutions to improve herd health, productivity and welfare for livestock producers.

• Devices and biodevices: Delivery systems, monitoring devices and other specialized equipment for veterinary medicine.

Primary species and markets served:

• Companion animals: Dogs, cats, horses and other pets represent a large and growing portion of revenue, driven by higher per-animal spend on diagnostics, pharmaceuticals and preventive treatments.

• Livestock/production animals: Cattle, swine, poultry and aquaculture customers rely on vaccines, anti-infectives and herd-management tools to improve productivity and disease control.

The balance between companion-animal and production-animal revenue varies by period and is disclosed in the company’s segment reporting and annual filings.

Financial profile and key metrics

Investors who follow the zts stock symbol typically track a set of standard financial metrics to evaluate the company’s performance and valuation. Key metrics include:

• Revenue and revenue growth: Top-line sales trends, broken down by product category and geography. Zoetis’s revenue history and multi-year growth rates are published in the annual report and Form 10-K.

• Net income and margins: Profitability measured by net income, operating margin and adjusted EBITDA. Analysts often reference non-GAAP adjusted metrics presented by the company.

• Market capitalization: The total market value of outstanding shares as reflected by the zts stock symbol price times shares outstanding. Market cap is commonly shown on financial websites and tradedata platforms.

• Price-to-earnings (P/E) ratio: A frequently used valuation multiple, though investors also use EV/EBITDA, price-to-sales and other metrics for comparisons across peers.

• Debt levels and leverage: Total debt, net debt and leverage ratios (such as net debt / adjusted EBITDA) to assess balance-sheet strength.

• Free cash flow: Cash generation used for dividends, share repurchases and acquisitions.

• Dividend metrics: Dividend per share, dividend yield and payout ratio are part of shareholder-return analysis.

As an example snapshot, investors often cite market-data providers for a dated summary. As of June 1, 2024, according to a market-data source, Zoetis’s market capitalization and liquidity metrics were publicly reported on mainstream financial pages; consult those services for the exact numbers and the latest updates. For the most current, verifiable figures, review the company’s latest Form 10-Q or 10-K and up-to-date quotes from recognized market-data providers.

Note: This article is informational and does not provide investment advice or predictions about future performance.

Historical stock price performance

The zts stock symbol has a trading history that reflects company fundamentals, earnings cycles, product approvals, regulatory decisions and broader market conditions. Key points for investors to consider:

• 52-week range and historical volatility: Financial pages provide the 52-week high and low, beta (volatility versus the market), and historical price charts (daily, weekly, monthly). These measures help investors understand recent price moves and longer-term trends.

• Multi-year trends: Over multi-year horizons, the zts stock symbol has historically reflected steady revenue growth in the animal-health sector and has responded to major corporate events such as acquisitions, product launches and earnings surprises.

• Event-driven moves: Notable price movements can occur around quarterly earnings releases, guidance updates, major acquisitions, product approvals/recalls, or macroeconomic events impacting animal-protein demand.

• Where to obtain historical data: Market-data providers, brokerage platforms and the company’s investor relations site offer downloadable historical price data and interactive charts. For analysis, combine price history with volume data and corporate-event calendars.

Example: For a dated snapshot, many investors reference authoritative financial outlets for price histories. As of June 1, 2024, historical charts and 52-week metrics for the zts stock symbol were available on mainstream finance sites; for exact price points and percent moves, refer to those providers or the brokerage platform you use.

Dividends and shareholder returns

Zoetis maintains a dividend policy and has distributed dividends to shareholders periodically. Key points:

• Dividend policy: Zoetis’s board of directors determines dividend levels and payout frequency. Dividend policy details and updates are published in investor communications and press releases.

• Dividend history and yield: The company has a documented history of dividend payments since listing. Dividend yield (annual dividend per share divided by share price) changes with the stock price and is reported by market-data services.

• Share repurchases: In addition to dividends, Zoetis has used share-repurchase programs at times to return capital, subject to board authorization and market conditions. Repurchase activity is disclosed in Form 10-Q and Form 10-K filings.

Investors interested in income characteristics should examine the most recent proxy statements, dividend announcements and the investor relations page for historical payouts and program authorizations.

Ownership and major shareholders

Ownership patterns for the zts stock symbol typically include a mix of institutional investors, mutual funds, exchange-traded funds (ETFs) and individual retail shareholders. Points to note:

• Institutional ownership: Large mutual funds, pension funds and asset managers often hold shares in Zoetis and report positions in regulatory filings (such as 13F filings for U.S. institutional managers).

• Insider holdings: Officers and directors may own shares; their holdings and transactions are disclosed in Forms 4 and DEF 14A (proxy statements).

• Public filings as sources: For verified ownership data, consult institutional filings (13F), the company’s proxy statement and Form 10-K, where beneficial ownership stakes and major shareholders are disclosed.

Observing changes in institutional positioning and insider activity can provide context about market sentiment regarding the zts stock symbol, but such data should be used together with fundamental analysis and not as sole decision criteria.

Analysts coverage and valuation

The zts stock symbol is covered by sell-side analysts and independent equity researchers. Common features of analyst coverage include:

• Analyst ratings: Coverage typically shows a mix of buy/hold/sell opinions and price targets. Ratings and targets update with earnings, significant transactions, or material news.

• Valuation methods: Analysts often use comparable-company analysis (multiples like P/E or EV/EBITDA), discounted cash flow (DCF) models and sum-of-the-parts approaches when valuing the business segments.

• Consensus metrics: Aggregate price targets and rating tallies can be found on financial platforms that compile analyst reports.

Investors should consult the latest analyst reports and disclosures for up-to-date views; analyst opinions are informational and should not be taken as personalized investment advice.

Risks and controversies

Investing in the zts stock symbol, like any equity, carries risks and company-specific operational exposures. Principal risk categories include:

• Regulatory risk: Veterinary medicines and vaccines require regulatory approvals; delays or adverse rulings can affect revenue and product launches.

• R&D and product performance: Clinical setbacks, lower-than-expected efficacy or competitive products can affect sales of new launches.

• Competition: The animal-health market features established global competitors and regional players offering alternative products and pricing pressures.

• Supply chain and manufacturing: Disruptions in manufacturing, supply-chain constraints or quality-control issues can temporarily affect product availability and sales.

• Legal and litigation risk: Zoetis, like other large pharmaceutical companies, may face regulatory investigations or litigation related to product liability, marketing practices or intellectual property. Material legal matters are disclosed in SEC filings.

• Macroeconomic factors: Changes in consumer spending on pets, commodity prices affecting livestock producers, and foreign-exchange movements can influence sales and margins.

• Concentration risk: Product concentration or customer-concentration for particular markets may create single-event sensitivities.

For any reported controversies or material legal matters, investors should read the company’s Form 10-Q and 10-K disclosures and reliable news reporting. As of specific dates, regulatory filings provide the most authoritative statements on pending litigation or investigations.

How to trade ZTS

Practical trading notes for investors looking to transact the zts stock symbol:

• Trading hours: The primary market for ZTS (NYSE) is open Monday through Friday with regular U.S. market hours. Pre-market and after-hours trading may be available on many broker platforms with wider spreads and lower liquidity.

• Broker platforms and access: Retail investors can trade ZTS through a range of brokerage platforms and trading apps. For users of Web3 custody or wallets, Bitget Wallet is recommended for related crypto-native features, and Bitget offers trading services where equities or equity-like products might be offered depending on jurisdiction and product scope. Always confirm with your broker which assets are supported and whether fractional shares or options trading are available.

• Order types: Common order types include market orders, limit orders, stop orders and extended-hours orders. Use limit orders to control execution price in volatile or low-liquidity sessions.

• Fractional shares and options: Some brokers offer fractional share purchases or options contracts on ZTS. Availability depends on the brokerage and local regulations. Make sure to check option listings and expiration cycles if you intend to trade options on ZTS.

• Settlement and market-data considerations: U.S. equities commonly settle on a T+2 basis (trade date plus two business days) for regular-way trades. Real-time quotes and level-2 market depth may be available through advanced broker subscriptions.

• Taxes and account types: Consider tax consequences for dividends, capital gains and account type (taxable brokerage, retirement accounts). Consult tax professionals for personalized guidance.

Note: This section provides operational information and not investment advice. Confirm platform features and legal availability in your jurisdiction.

Peers and competitive landscape

Zoetis operates in the animal-health and veterinary-products sector. Principal peers and competitors (global or regional) include companies focused on veterinary pharmaceuticals, vaccines and diagnostics. When comparing the zts stock symbol to peers, analysts commonly examine revenue mix (companion vs. production animals), R&D pipelines, margin profiles and geographic exposure.

Examples of the competitive landscape include global animal-health specialists and diversified healthcare companies with animal-health divisions. When building peer comparisons, analysts typically select companies with similar business models and scale to create meaningful valuation and operating comparisons.

Index and ETF inclusion

Inclusion in major indices and ETFs can affect liquidity and institutional demand for the zts stock symbol.

• Index membership: Zoetis may be included in large-market indices that track U.S. equities or healthcare sector constituents. Inclusion criteria and periodic rebalancing can change as market capitalization and float evolve.

• ETFs and sector funds: The zts stock symbol is commonly held by sector ETFs, healthcare and veterinary-focused funds, and broad-market ETFs that track large-cap U.S. equities. Holdings disclosures from ETF issuers identify constituent weightings, which can affect demand and liquidity for the stock.

Investors tracking passive flows should monitor index reconstitution announcements and ETF quarterly disclosures for changes in holdings that could influence the zts stock symbol.

Corporate governance

Zoetis’s corporate governance framework includes a board of directors, executive leadership team and governance policies disclosed in proxy statements and investor materials.

• Board structure and independence: The board includes independent directors and committee structures (audit, compensation, nominating/governance) consistent with corporate-governance best practices. Committee charters and director biographies are provided in the annual proxy statement.

• Key executives: The CEO, CFO and other senior leaders are listed in corporate disclosures with background, compensation and tenure details.

• Governance practices: Shareholder engagement, executive compensation policies, and governance initiatives (including ESG-related practices) are discussed in annual reports and sustainability disclosures.

Investors seeking in-depth governance information should consult the company’s DEF 14A (proxy statement) and investor-relations governance pages.

Investor resources and filings

Primary sources for verified information about Zoetis and the zts stock symbol include:

• Company investor relations materials: Earnings releases, investor presentations, and investor-day slide decks provide management commentary and detailed financial tables.

• SEC filings: Form 10-K (annual report), Form 10-Q (quarterly report) and Form 8-K (current reports) contain audited financials, risk-factor disclosures and material event announcements.

• Earnings calls and transcripts: Quarterly and annual earnings calls present management’s narrative; transcripts often give additional color on results and guidance.

• Market-data providers: Financial news sites and data vendors provide real-time quotes, analyst coverage, historical charts and aggregated consensus estimates. As of June 1, 2024, major providers published market-cap and liquidity metrics for ZTS — consult those services for time-stamped figures.

• Regulatory filings for insider transactions: Forms 3, 4 and 5 capture officer and director trades and holdings.

When looking up data, prefer primary company filings and audited financial statements for the most reliable and legally required disclosures.

See also

• Animal health industry overview
• Veterinary pharmaceuticals and vaccines
• Companion-animal market dynamics
• Corporate spin-offs and IPOs

References and external links

Sources used to prepare this guide include publicly available company disclosures and mainstream market-data outlets. For dated reporting and verifiable figures, consult the following types of sources (search the listed sources on your preferred market-data platform or the company’s investor-relations page):

• Zoetis Investor Relations (company filings, press releases and investor presentations)
• SEC filings (Form 10-K, Form 10-Q, Form 8-K, proxy statements)
• Major financial news providers and market-data services (for example, Yahoo Finance, Reuters, CNBC and recognized equity research platforms)

As a snapshot example of publicly reported figures: As of June 1, 2024, according to a mainstream market-data provider, the zts stock symbol’s market capitalization and average daily trading volume were reported on standard finance pages; readers should verify the exact, current numbers with their chosen data vendor or broker. For regulatory or legal events, rely on the company’s official press releases and SEC filings dated at the time of each event.

Further exploration and up-to-date market data are available through the company investor-relations pages and SEC filing repositories.

Trading note and platform recommendation: If you plan to monitor or trade shares under the zts stock symbol, consider using a trusted brokerage or trading platform. For users interested in integrated custody and trading experiences that bridge traditional markets and Web3, Bitget and Bitget Wallet are options to explore where supported. Confirm local availability, fees, and supported products before trading.

Frequently asked questions (FAQ)

What does the zts stock symbol mean?

The zts stock symbol is the ticker used to identify Zoetis Inc. common shares on the New York Stock Exchange. It is the unique short code investors use to quote and trade the company’s stock.

Where does ZTS trade and in what currency?

ZTS trades on the NYSE (sometimes shown as XNYS in data feeds) and is quoted in U.S. dollars.

How can I find up-to-date financial metrics for ZTS?

For current revenue, earnings, market capitalization and dividend metrics, consult the company’s latest SEC filings and mainstream market-data providers. The Form 10-Q and 10-K are authoritative for reported financials.

Does Zoetis pay a dividend?

Yes — Zoetis has a dividend policy and periodically pays dividends. Check investor relations or recent press releases for the current dividend rate and announcement date.

What are the major risks for investors in ZTS?

Main risks include regulatory approvals for medicines, product performance, competitive pressures, supply-chain issues and potential litigation. The company’s SEC filings provide detail on risk factors.

Further exploration: explore Zoetis investor materials and audited SEC filings for the most authoritative information about the zts stock symbol and the company’s performance. For trading and custody tools tied to modern wallets and an integrated platform experience, consider Bitget services where available in your jurisdiction to access market data and execution features.